ライフサイエンスコーパス: Bacille Calmette-Guerin

1 m smegmatis , Mycobacterium tuberculosis and bacille Calmette-Guerin.

2 ce and C57BL/6 mice previously infected with bacille Calmette-Guerin.

3 ination of 10 of these 19 patients with live bacille Calmette-Guerin.

4 in or for those who cannot be immunized with bacille Calmette-Guerin.

5 h superficial bladder cancer who have failed bacille Calmette-Guerin.

6 autologous, DNP-modified vaccine mixed with bacille Calmette-Guerin.

7 acteria such as M. tuberculosis and M. bovis Bacille-Calmette-Guerin.

8 od to restrict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis w

9 n vitro activity against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

10 In sharp contrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutan

11 s to study the uptake of Mycobacterium bovis bacille Calmette Guerin (BCG) into murine macrophages.

12 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberc

13 from tuberculosis every year even though the bacille Calmette Guerin (BCG) vaccine has been available

14 ed as an intravesical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional c

15 led whole-promastigote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly red

16 rget (ESAT)-6, that are absent from M. bovis bacille Calmette-Guerin (BCG) and most environmental myc

17 ow-growing mycobacteria, Mycobacterium bovis bacille Calmette-Guerin (BCG) and Mycobacterium avium, b

18 g to inhibit mycobacterial growth, including Bacille Calmette-Guerin (BCG) and Mycobacterium tubercul

19 ble to follow the migration of live M. bovis Bacille Calmette-Guerin (BCG) and to observe interaction

20 A human mycobacterial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycob

21 Use of bacille Calmette-Guerin (BCG) as a surrogate for human M

22 Intravesical immunotherapy using Bacille Calmette-Guerin (BCG) attenuated bacteria delive

23 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licen

24 c and CB6F1) were vaccinated with a range of Bacille Calmette-Guerin (BCG) Danish doses from 3 x 10(5

25 Intra-dermal Bacille Calmette-Guerin (BCG) delivery is the only licen

26 Maternal priming with bacille Calmette-Guerin (BCG) has been associated with r

27 nst pediatric tuberculosis, vaccination with bacille Calmette-Guerin (BCG) has been reported to confe

28 uated strain of Mycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a

29 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in p

30 Bacille Calmette-Guerin (BCG) immunity can be studied as

31 tify immune correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the

32 CD8 T cells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-

33 Inoculation of Mycobacterium bovis Bacille Calmette-Guerin (BCG) in the skin mobilizes loca

34 When PMCs were stimulated with bacille Calmette-Guerin (BCG) in vitro, they expressed I

35 Mycobacterium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

36 obacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG) in which a very high propo

37 d major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memo

38 th T cells responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt gran

39 al iron-enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

40 The tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organ

41 Bacille Calmette-Guerin (BCG) is a live, attenuated stra

42 Bacille Calmette-Guerin (BCG) is an attenuated strain of

43 urrently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used va

44 demic and vaccination at birth with M. bovis bacille Calmette-Guerin (BCG) is widely used.

45 e have shown that systemic administration of Bacille Calmette-Guerin (BCG) or beta-glucan reprograms

46 o, pleural mesothelial cells stimulated with bacille Calmette-Guerin (BCG) or interferon (IFN)-gamma

47 Intravenous (i.v.) vaccination with Bacille Calmette-Guerin (BCG) provides nearly complete p

48 gets of the partially efficacious TB vaccine bacille Calmette-Guerin (BCG) remain poorly defined.

49 A recent clinical trial demonstrated that Bacille Calmette-Guerin (BCG) revaccination of adolescen

50 In a previous phase 2 trial, bacille Calmette-Guerin (BCG) revaccination was not show

51 he characterisation in mice of a noninvasive bacille Calmette-Guerin (BCG) skin challenge model for a

52 The bacille Calmette-Guerin (BCG) tuberculosis vaccine has i

53 with IGRAs in individuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy

54 sate to detect antibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tub

55 sessed using intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate

56 Bacille Calmette-Guerin (BCG) vaccination can confer non

57 Bacille Calmette-Guerin (BCG) vaccination can potentiall

58 ction with environmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the

59 Bacille Calmette-Guerin (BCG) vaccination has been sugge

60 By studying Bacille Calmette-Guerin (BCG) vaccination in a human coh

61 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy vol

62 Bacille Calmette-Guerin (BCG) vaccination induces a mark

63 Bacille Calmette-Guerin (BCG) vaccination may induce per

64 Population-level data have suggested that bacille Calmette-Guerin (BCG) vaccination may lessen the

65 Bacille Calmette-Guerin (BCG) vaccination remains a corn

66 bacterial Ags in the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T

67 Bacille Calmette-Guerin (BCG) vaccination, known to indu

68 mized to receive percutaneous or intradermal bacille Calmette-Guerin (BCG) vaccination.

69 Approximately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each yea

70 tection conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted a

71 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protect

72 Bacille Calmette-Guerin (BCG) vaccine can elicit good T(

73 Bacille Calmette-Guerin (BCG) vaccine could play a role

74 Policies regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis v

75 Maternal priming with the Bacille Calmette-Guerin (BCG) vaccine has been associate

76 The bacille Calmette-Guerin (BCG) vaccine has immunomodulato

77 The existence of therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significa

78 er (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tub

79 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried

80 torical trends, to query the efficacy of the bacille Calmette-Guerin (BCG) vaccine, and to uncover ta

81 whole-cell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

82 )mac-infected macaques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG,

83 radiated autologous tumor cells admixed with bacille Calmette-Guerin (BCG) were used to vaccinate pat

84 We have previously established that bacille Calmette-Guerin (BCG), an attenuated form of Myc

85 Bacille Calmette-Guerin (BCG), an attenuated strain of M

86 The cells were infected with bacille Calmette-Guerin (BCG), and intracellular mycobac

87 transposed apparently randomly in M. phlei, Bacille Calmette-Guerin (BCG), and M. tuberculosis.

88 the tuberculosis vaccine Mycobacterium bovis bacille Calmette-Guerin (BCG), another live attenuated v

89 apy with the standard-of-care immunotherapy, bacille Calmette-Guerin (BCG), constitute a challenging

90 Certain vaccines, such as Bacille Calmette-Guerin (BCG), have nonspecific effects,

91 ial heterologous effects of vaccines such as bacille Calmette-Guerin (BCG), the licensed TB vaccine.

92 Bacille Calmette-Guerin (BCG), the only approved Mycobac

93 Bacille Calmette-Guerin (BCG), the only currently licenc

94 is expressed in M. tuberculosis and M. bovis Bacille Calmette-Guerin (BCG), using reverse transcripti

95 obacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce

96 rus of macaques (SIVmac)/Mycobacterium bovis bacille Calmette-Guerin (BCG)-coinfected macaque model.

97 an immunodeficiency virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4

98 tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD

99 ial protection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using a

100 In Mycobacterium bovis Bacille Calmette-Guerin (BCG)-infected wild-type mice, t

101 N-gamma-secreting T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

102 cterium bovis bloodstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with h

103 reaction directed against the mycobacterium bacille Calmette-Guerin (BCG).

104 t two treatments, PMCV was administered with bacille Calmette-Guerin (BCG).

105 teria such as Mycobacterium tuberculosis and bacille Calmette-Guerin (BCG).

106 acrophage infection with Mycobacterium bovis bacille Calmette-Guerin (BCG).

107 efficacy of the currently licensed vaccine, Bacille Calmette-Guerin (BCG).

108 e Mycobacterium bovis-derived vaccine strain bacille Calmette-Guerin (BCG).

109 h an attenuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

110 ing the live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

111 cerebrally infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

112 rculosis but not the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

113 ts were vaccinated with one of four doses of bacille Calmette-Guerin (BCG): The doses contained very

114 45 countries was 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for d

115 ulosis (Mtb) infection following intravenous Bacille-Calmette Guerin (BCG) vaccination of nonhuman pr

116 igs that had or had not been vaccinated with Bacille-Calmette Guerin (BCG).

117 While bacille-calmette-guerin (BCG) vaccination is one of the

118 One promising avenue is with the bacille-calmette-guerin (BCG) vaccine in autoimmune type

119 Although the Bacille-Calmette-Guerin (BCG) vaccine is used to prevent

120 pulmonary infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

121 d compound pyrazinamide restricted growth of bacille Calmette-Guerin but not wild-type Mycobacterium

122 ection and inhibited NO-dependent killing of bacille Calmette-Guerin by macrophages.

123 We show in this article that although bacille Calmette-Guerin controlled M. tuberculosis growt

124 /E178K found in CRP from Mycobacterium bovis Bacille Calmette-Guerin (CRP(BCG)).

125 esus monkeys were immunized with recombinant bacille Calmette-Guerin expressing the full-length measl

126 toplasmically into macrophages infected with bacille Calmette-Guerin expressing the green fluorescent

127 n to be an effective combination therapy for bacille Calmette-Guerin failures.

128 apy is proposed as a second-line therapy for bacille Calmette-Guerin failures.

129 The addition of interferon to bacille Calmette-Guerin has proven to be an effective co

130 infected with Mycobacterium tuberculosis or bacille Calmette-Guerin have been shown to facilitate pr

131 Intravesical bacille Calmette-Guerin (including a maintenance regimen

132 ), interleukin-1beta (IL-1beta), and IL-6 in bacille Calmette-Guerin-infected macrophages and of TNF-

133 Bacille Calmette-Guerin is the most effective therapy fo

134 Mycobacterium tuberculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immun

135 nstrate that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thia

136 cells within hepatic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

137 induced by infection with M. tuberculosis or bacille Calmette-Guerin, or treatment with LPS or TNF-al

138 vaccination involves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective

139 troduced and existing ones improved to treat bacille Calmette-Guerin-refractory superficial bladder c

140 cterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in bot

141 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fol

142 tients who receive intravesical therapy with bacille Calmette-Guerin should be considered for ongoing

143 cterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established gr

144 acterial antigens shown previously to induce bacille Calmette-Guerin-specific gammadelta T cells.

145 chronic medical illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially aff

146 Bacille Calmette Guerin-vaccinated children were more li

147 Between December 2013 and January 2016, 36 bacille Calmette-Guerin-vaccinated, healthy UK adults we

148 candidate, M72/AS01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and

149 eactivity to nontuberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a pr

150 Bacille Calmette-Guerin vaccination, tuberculosis preval

151 tory of a positive PPD skin test result or a bacille Calmette-Guerin vaccination.

152 is challenge compared with standard M. bovis bacille Calmette-Guerin vaccination.

153 fers poor specificity in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in

154 Research into the bacille Calmette-Guerin vaccine demonstrated the importa

155 d, controlled trials of the effectiveness of bacille Calmette-Guerin vaccine in preventing active tub

156 The bacille Calmette-Guerin vaccine provides very efficient

157 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS an

158 the variable efficacy of the currently used bacille Calmette-Guerin vaccine.

159 inguish exposure to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently l

160 The BCG (Bacille Calmette-Guerin) vaccine, introduced 100 years a

161 alization rates and responses to tetanus and Bacille Calmette-Guerin vaccines among HEU and HUU vacci

162 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-t